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Platinum complexes (cisplatin, carboplatin and oxaliplatin) are effective anticancer 
agents. However the major drawbacks of platinum chemotherapy are toxic side effects and 
resistance.  The affinity of platinum complexes to sulfur donor ligands of side chains of 
methionine and cysteine amino acids was assumed to be responsible for toxicity and 
resistance. Recently, it was found that the reaction of platinum complex with proteins 
containing sulfur donor ligands could actually favor its anticancer activity. Copper 
transporter 1 (Ctr 1), a protein involved in the transport of copper into the cell, also helps in 
the influx of cisplatin by binding to N-terminal domain of Ctr 1 which is rich in methionine 
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and histidine residues. A better understanding of how the size and shape of amine ligand, 
and leaving groups affect the reaction of platinum (II) complexes with methionine could 
give new ways to optimize its anticancer activity. This preliminary research focuses to 
answer this by HPLC-UV-VIS analysis of bulky platinum complexes including 
[Pt(dien)Cl]Cl, Pt(Me4en)(NO3)2 and Pt(en)(NO3)2 with two methionine containing small 
peptides that serve as models for protein interactions.
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I. INTRODUCTION 
A. History 
Cancer is a group of symptoms characterized by uncontrolled growth and spread 
of abnormal cells. It is the second most common cause of death in the US, exceeded only 
by heart disease. In the US, cancer accounts for nearly 1 of every 4 deaths (American 
Chemical Society, Cancer Facts and figures, 2009). It is caused by both external factors 
(tobacco, infectious organisms, chemicals, and radiation) and internal factors (inherited 
mutations, hormones, immune conditions, and mutations that occur from metabolism). 
The treatment options available are surgery, radiation, chemotherapy, hormone therapy, 
biological therapy, and targeted therapy.  
The use of cancer chemotherapy can be traced back to 1940s when the chemical 
warfare agent nitrogen mustard was found to be an effective anticancer drug 1. 
Nowadays, chemotherapy is the first line of treatment for various cancers but is offset by 
various side effects and resistance accompanying them.  
Almost 5000 years ago, metal complexes were used for various medicinal 
applications 2. As metal complexes have a positively charged central atom, they are 
expected to bind strongly to negatively charged biomolecules such as amino acids, 
peptides, proteins and nucleic acids. The major drawback with the use of metal 
complexes is their bioaccumulation and clearance leading to unwanted side effects 3. 
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Examples of anticancer metal complexes using platinum are cisplatin, carboplatin 
and oxaliplatin (Fig 1.1). Cisplatin was synthesized for the first time by Michael Peyrone 
in 1845 4. It was not until 1961 that its anticancer activity was elucidated. The anticancer 
activity was discovered serendipitously by Barnett Rosenberg, a biophysicist at the 
University of Michigan, when he was conducting an experiment to determine if the 
electric currents affect cell division. Initially, by the presence of long filamentous 
bacterial cells instead of classical sausage shape, he found that the platinum hydrolysis 
products from the inert platinum electrodes inhibited cell division, later confirmed by a 
series of other investigations that platinum can inhibit cell growth. It was also concluded 
by Rosenberg and co-workers that cis form of the platinum complex was responsible for 
cytotoxic effect and trans- form was inactive 5.  
In December 1978, cisplatin was the first platinum complex approved by the US 
FDA for the treatment of testicular cancer. It is also used for the treatment of other 
cancers such as ovarian, cervical, head and neck, and non-small-cell lung cancer 11. Due 
to lack of selectivity, cisplatin shows many side effects, which are only partially 
reversible by stopping the therapy; these include renal impairment, neurotoxicity, 
ototoxicity and severe anemia 3, 6. In order to overcome these shortcomings second 
generation platinum drugs with improved toxicological profiles and third generation 
platinum drugs to overcome cisplatin resistance have been introduced. 
The second-generation platinum drug carboplatin, [Pt(C6H6O4)(NH3)2] 6, has 
fewer toxic side effects than cisplatin and is more easily used in combination therapy. 
Carboplatin is modified by replacing chloride leaving groups of cisplatin with 1,1-
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cyclobutanedicarboxylate (CBDCA) ring which causes decreased toxicity due to slower 
rate of conversion to active species. In July 2003, the US FDA approved carboplatin for 
the treatment of ovarian cancer. 
The third generation platinum drugs have decreased resistance to cisplatin 
resistant tumors 8. Oxaliplatin is the only third generation platinum drug approved for the 
treatment of colorectal cancer by the US FDA in January 2005. This group of compounds 
differs in amines and does not have the classical cis-diamine structure with two leaving 
groups 3. 
 
Figure 1.1. FDA approved platinum complexes 
B. Chemistry of Platinum complexes 
The general structural formula of most of the platinum complexes is cis [PtX2 
(NHR2)2]. In which R = organic fragment, X = leaving group like chloride, carboxylate, 
nitrate or oxalate 3. 
Most of the platinum anticancer complexes follow a general set of structural rules 5.  
i) The complexes exchange only some of their ligands quickly in reaction with  
      biological molecules. 
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ii) The complexes should be electrically neutral, although the active form may be  
      charged after undergoing ligand exchange. 
iii) The geometry of the complexes is either square planar or octahedral. 
iv) The complexes should have at least one N-H group which is required for 
      hydrogen bonding with the biological target. 
v) Two cis-monodentate or one bidentate leaving group is required. 
vi) The rates of exchange of these groups should fall into a restricted region; since 
too high a reactivity will mean that the chemical reacts immediately with blood 
constituents and never gets to the tumor. 
vii)  The leaving groups should be approximately 3.4 Å apart on the molecule. 
Deviation from these set of rules do exit, such as the trans- form of cisplatin with 
bulkier ligands that has also showed anticancer activity 9. 
Ligand exchange kinetics of platinum complexes plays an important role in the 
anticancer activity 3, 10. The platinum ligand bond, which has a thermodynamic strength 
of a typical coordination bond, is much weaker than C-C, C-N, or C-O single and double 
bonds. The ligand exchange behavior provides a reaction of minutes to days so that it can 
reach its target site despite of various interactions. In comparison to cisplatin, carboplatin 
and oxaliplatin have slower ligand exchange kinetics, which shows its decreased side 
effects and resistance. 
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C. Mechanism of action 
Cisplatin, Carboplatin and Oxaliplatin are administered I.V because of their 
insoluble nature in aqueous systems. Once in the bloodstream they enter the cell by either 
passive or active transport. The difference in chloride concentration across the cell 
membrane helps in the passive diffusion of cisplatin into the cell 3, 11. It was found 
recently that there exists a relationship between the copper and platinum transport and 
metabolism. Song et al, found that cisplatin, carboplatin and oxaliplatin interact with Ctr 
1, a high affinity copper transporter protein 12, 13. This protein helps in the active influx of 
platinum complexes. It has also been found that efflux proteins are also present for 
excretion of platinum complexes 14. The exporter proteins that are involved in the efflux 
of platinum complexes are ATP-binding cassette transporter family C2 (ABCC2, also 
known as Mrp2/AB or ATP7B) 15, 16. 
Once inside the cell, cisplatin undergoes aquation to form cationic platinum 
complexes by losing two chloride ions. This aquated form is more reactive than the 
neutral cisplatin. The cationic platinum complexes bind to DNA at N7 position of 
guanine forming GG intrastrand crosslinks (Fig 1.2.) 11. In case of carboplatin and 
oxaliplatin, these interactions with DNA occur at the position where cyclobutane-1,1-
dicarboxylate (CBDCA) and the oxalate ligands are attached to platinum respectively 11. 
Binding to DNA leads to distortion of double helical structure of DNA thus impairing its 
processing. The 1, 2-intra strand cross links bend DNA significantly towards the major 
groove, exposing a wide shallow minor groove surface, to which several proteins bind. 
These proteins include high-mobility group (HMG) proteins, repair proteins, transcription 
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factors and Histone H1 proteins. Binding of these proteins will lead to replication 
inhibition, transcription inhibition, cell cycle arrest and cell death 12. Therefore, Pt-DNA 
adducts along with the proteins that bind to it promotes cytotoxicity. 
In carboplatin, the formation of a six membered ring by the leaving group and 
platinum atom, promotes good aqueous solubility and greater stability, hence showing 
decreased side effects while maintaining the same therapeutic profile as cisplatin 17, 18. 
The decreased cross resistance of oxaliplatin is contributed due to bulky 
diaminocyclohexane (DACH) carrier ligand, which may enhance binding of damage-
recognition proteins on the platinated DNA 19. The molecular mechanisms responsible for 
resistance to platinum anticancer complexes include inactivation by glutathione, 
metallothionein or other sulfur containing molecules, increased repair of cisplatin 
adducts, reduced platinum accumulation by changing the profile of uptake/efflux, 
increased adducts tolerance and failure of apoptic pathways 11. 
 
Figure 1.2. Schematic representation of mechanism of action of cisplatin 11 
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D. Reaction of Platinum complexes with proteins 
Many biomolecules can interact with platinum complexes. Amino acids present 
metal ions with a variety of potential donor atoms. In amino acids, sulfur donor residue is 
one of the primary targets owing to its relative softness 20 for platinum. Platinum binds 
preferentially to the thioether functional group of methionine rather than to thiol group of 
cysteine because thiol groups form disulfide bonds.  Platinum can also bind to lone pair 
of nitrogen atoms of amino acid (histidine), but only in the absence of S-donor groups 5. 
Hence methionine, cysteine and histidine are amino acids that may interact with platinum 
complexes. 
How platinum complexes are able to react with DNA targets despite large 
amounts of sulfur containing biomolecules has been a question of debate. Two kinds of 
approaches can be put forward; firstly, reaction of platinum complexes with proteins 
causes toxicity and resistance 21 - 25 and secondly, interaction of platinum complexes 
favors anticancer activity 11. 
Traditionally, it was understood that toxicity and resistance may be induced by 
coordination of platinum complexes with the sulfur containing residues of amino acids 26. 
It was found that important enzymes were inhibited by reduction of sulfur groups. The 
total number of protein-bound thiol groups is depleted (14 %) in kidneys after cisplatin 
administration especially in mitochondrial fractions 22, 23. Aull et al; found that both cis- 
and trans-platinum inhibits the enzyme thymidylate synthetase in vitro 24. For 
nephrotoxicity, the enzyme adenosine triphosphatase, which is important for kidney 
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function, is inhibited by cisplatin though at high concentrations impossible to achieve in 
vivo 25. 
Platinum complexes may also bind to amino acids in a protein to show positive 
effects as well. The high affinity of platinum complexes for sulfur atoms and abundance 
of sulfur containing molecules in cytosol and nucleus of cell has prompted to check if 
platinum – sulfur interaction could serve as a reservoir for platination 27 or also for active 
import of platinum complexes into the cell 5. Research has been conducted to study 
intermolecular and intramolecular competition reactions to verify the binding preference 
of platinum in the presence of both sulfur groups and N7 atoms of nucleobases.  
Intramolecular studies have been performed by using molecule containing both 
sulfur and N7 group function i.e. adenosyl – L – Homocysteine, S-Guanosyl – L – 
Homocysteine, Met – d(TPG) and Met – d(TpGpG) 27 - 30. Intermolecular studies were 
done using either methionine or methylated gluthatione (GSME) as the sulfur containing 
model and guanosine 5 - monophosphate (5`-GMP) and guanylyl (3-5) guanosine 
(dGpG) as N7 – containing models for DNA 29, 31, 32. All of these experiments concluded 
that initially platinum complexes react with sulfur groups as it is kinetically preferred but 
over a period of time sulfur atoms are replaced by N7 of guanine, which is 
thermodynamically favored. Therefore it may be understood that the reactions of sulfur 
groups with the platinum complexes can act as a reservoir for platinum or to form active 
intermediates, finally helping out in the platination of N7 guanine DNA 5. 
Recent reports have also demonstrated that platinum complexes (cisplatin, 
carboplatin and oxaliplatin) react with Ctr1, copper transporter 1 protein 12, 13, 33. The Ctr1 
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family represents evolutionary conserved transporters of copper that are present in yeast, 
plants, and mammals. All Ctr1 transporters contain three transmembrane domains, an 
NH2 terminal methionine rich motif consisting of three to five methionine in MxM and/or 
MxxxM arrangements, and a COOH-terminal cysteine or histidine motif 12. Platinum 
complexes interact with the Ctr1 at N terminal domain, rich in methionine and histidine 
residues, in 1:1 and 2:1 Pt:protein stoichiometries 13. 
Therefore, it can be summarized that platinum complexes has an affinity to 
interact with sulfur containing residues of amino acids. These interactions may favor 
platination of DNA at guanine by forming intermediates or acting as a reservoir for 
platinum and by favoring active transport of platinum complexes into the cell. 
The present research studies the effect of size and shape of amine ligand, and 
leaving groups on the reaction of platinum (II) diamine and triamine complexes with 
methionine containing peptides. It analyzes the reactions of three platinum complexes, 
[Pt(dien)Cl]Cl, [Pt(en)(NO3)2] and [Pt(Me4en)(NO3)2] with small peptides that serve as 
models for protein interactions by using high pressure liquid chromatography (HPLC). 
The peptide models used in this study are FMRF and ACTH. FMRF is a 4 amino acid 
peptide and ACTH is a 10 amino acid peptide. Both of these peptides contain a 
methionine residue.  
Previously, various studies have been performed on platinum complexes with 
models containing one or two amino acids, proteins and nucleotides. The knowledge of 
the interactions of these three platinum complexes with sulfur containing peptide models 
and competition between S & N donor in these systems is quite limiting. Siebert and 
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Sheldrick has investigated the pH dependent studies on the reaction of [Pt en (H2O2)]2+ 
with methionine containing di and tripeptides 34, 35. 
With this research work an attempt has been made to study the affect of bulk of 
ligands and leaving groups for the formation of Pt-S adducts and how much time is 
required for the whole reaction to complete.
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II. EXPERIMENTAL 
A. Materials used 
HPLC grade acetonitrile, pentafluoropropionic acid (PFP), monobasic sodium 
phosphate monohydrate, dibasic sodium phosphate, sodium chloride (NaCl), 
dichloroethylenediamine platinum (II) [Pt(en)Cl2], methanol, chloroform, acetone, silver 
nitrate, diethyl ether, potassium tetrachloroplatinate (K2PtCl4) and dimethyl sulfoxide 
(DMSO) were purchased from Sigma Aldrich. Deionized water was used for buffer and 
sample preparation. 
Two peptides, FMRF and ACTH (1-10) human were purchased from American 
Peptide Company for this study. FMRF is a 4 amino acid peptide with a molecular weight 
of 599.8 g. It has two phenylalanine residues, which help in detection of this peptide at 
254 nm. 
Sequence of FMRF:  Phe – Met – Arg – Phe 
ACTH is a 10 amino acid peptide and the functional groups of methionine and 
histidine are possible sites of reaction. The presence of tryptophan and tyrosine helps in 
detection of this peptide at 280 nm. 
Sequence of ACTH: Ser – Tyr – Ser – Met – His – Phe – Arg – Trp – Gly  
14 
 
  
B.  HPLC  
Analytical HPLC (High Pressure Liquid Chromatography) was performed with a 
Hitachi Elite Lachrome high-pressure liquid chromatograph equipped with a L-2130 
pump, manual injector, a 20-µl injection loop, and a variable-wavelength Hitachi L-2400 
UV-Vis detector. Cation exchange chromatography was performed with a Supelco 
Discovery BIO PoylMA SCX column (5 cm x 4.6 mm, dp 5µm). Reverse phase liquid 
chromatography (RPLC) was performed with an Atlantis dC 18 column (2.1 x 150 mm, 
dp 5 µm). 
For cation exchange HPLC, gradient buffer containing mono and dibasic sodium 
phosphate were used. For Reverse phase HPLC isocratic buffer solution containing 0.2% 
pentafluoropropionic acid (PFP), 4% Acetonitrile (ACN) in D.I. water was used.  
C. Preparation of buffer solutions 
For cation exchange chromatography, sodium phosphate buffers with gradient 
elution were used. 0.2 M monobasic stock was prepared by dissolving 13.6 g of 
monobasic sodium phosphate monohydrate in water and diluted to 500 ml. 0.2 M dibasic 
stock solution was prepared by dissolving 14.2 g of dibasic sodium phosphate in water 
and diluted to 500 ml. Buffer A was prepared by mixing 87.7 ml of monobasic stock 
solution and 12.3 ml of dibasic stock solution and diluted to 1 L by using D.I water to 
obtain a 0.02 M phosphate buffer with 6.0 pH. Buffer B was prepared in the same way as 
Buffer A and 29.2 g of NaCl was also added to final volume of 1 L solution to get 0.5 M 
NaCl. 
15 
 
  
For Reverse Phase Liquid Chromatography (RPLC), an isocratic buffer elution 
method was used and buffer solution was prepared according to the study of Sheldrick et 
al 36. Buffer was prepared by mixing 40 ml of acetonitrile (4%), 2 ml of pentafluoro 
propionic acid (0.2%) in 958 ml of water. pH of the solution was 2 + 0.5. Both of these 
buffer solutions were vaccum filtered before used for HPLC. 
D. Synthesis of chlorodiethylenetriammineplatinum [II] chloride ([Pt(dien)Cl]Cl)  
Pt(dmso)2Cl2 was prepared according to the method described by Price et al 36. A 
solution of dien (76.4 µl) in methanol (10 ml) was added with stirring to a suspension of 
cis – [Pt(dmso)2Cl] (0.3 g) in methanol (50 ml) and the mixture was refluxed for ca 1 h. 
The resulting colorless solution was concentrated in a rotary evaporator to ca 5 ml, 
cooled at room temperature and filtered to remove any unreacted cis-[Pt(dmso)2Cl2]. 
Chloroform (30 ml) was then added to precipitate the product as gelatinous white solid 
which became powdery upon stirring. The precipitate was filtered, washed with 
chloroform, diethyl ether, air dried, and recrystallized from a filtered aqueous solution (2 
ml) by careful addition of acetone. It was finally washed with acetone, diethyl ether and 
air dried 37. 
E. Synthesis of ethylenediamminedinitroplatinum [II] (Pt(en)(NO3)2) 
Dichloroethylenediamineplatinum (II) (Pt(en)Cl2) was converted to nitrate form 
by addition of silver nitrate. For every one mole of Pt(en)Cl2 two moles of silver nitrate 
was added along with 10 ml of water. The mixture was stirred overnight and filtered 
16 
 
  
through syringe filter to remove silver chloride precipitate.  The liquid was collected in a 
50 ml round bottom flask and evaporate to dryness using rotor evaporator. 
F.        Synthesis of ethylenediamminetetramethyldinitroplatinum [II] (Pt(Me4en)(NO3)2) 
     Pt(Me4en)I2 was synthesized analogously to the work of Cerasino et al 38. In this 7 
mM (1326.6 mg) of potassium iodide (KI) and 1 mM (416.6 mg) of potassium 
tetrachlorplatinate (K2PtCl4) was stirred in DI water (5 ml) for ~ 30 mins. The resulting 
solution was syringe filtered into 2.5 mmol (375 µl) of N,N,N',N' 
tetramethylethylenediamine and DI water (5 ml), and stirred for ~30 mins. The resulting 
solution containing Pt(Me4en)I2 was filtered , washed with DI water, ethanol and ether. 
Pt(Me4en)I2 was converted to nitrate according to the method described by 
Wimmer et al 39. Pt(Me4en)I2  was mixed with silver nitrate and acetone was added until 
it dissolved. The solution was stirred over night and gravity filtered to obtain 
Pt(Me4en)(NO3)2.
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III. RESULTS 
Platinum complexes with varying coordination sites and ligand bulk have been 
studied for their interaction with peptides. ACTH and FMRF peptides were purchase 
from American Peptide Company for this study. ACTH and FMRF contain internal 
methionine residue (Fig. 3.1a), which is a possible site for the reaction of platinum 
complexes. Additionally, ACTH contains a histidine (Fig. 3.1 b) residue that can also 
bind to platinum complexes. 
 
Figure 3.1. Structure of a) Methionine b) Histidine amino acids 
In this study, initially cation exchange chromatography (CEC) was used for the 
analysis of reaction of platinum complexes with peptides. CEC was carried out with 
mono and dibasic phosphate buffer solutions in D.I water by gradient elution method. It 
was unsuccessful mainly by broad peaks characterized by inefficient separation of 
adducts. 
C COOH
H
NH2
CH2
CH2
S
CH3 CH NH2HOOC
CH2
N
N
H
a) b) 
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Reverse phase HPLC was adopted to get a better separation of adducts formed. 
This method is based on a study by Sheldrick et al. In this type of analysis isocratic 
elution method was used. Buffer solution contained a mixture of ion pairing reagent, 
0.2% pentafluoro propionic acid along with 4 % acetonitrile in D.I. water. With this 
method, we were able to separate two reaction mixtures i.e. FMRF+Pt(en)(NO3)2 and 
FMRF+Pt(Me4en)(NO3)2. For other reaction mixtures, present RPLC method causes 
increase in pump pressure and decreased product separation, which hindered analysis. 
All the reaction mixtures are in 1:1 ratio except for Pt(en)(NO3)2/FMRF system in 
RPLC method. Sample for injection was prepared by first dissolving the platinum 
complex in deionized water and then peptide was added to get the required molar ratio. 
Next, it was filtered through syringe filter and the filtered solution was injected in HPLC. 
After the completion of one HPLC run, sample was injected again from the same syringe. 
The reaction was monitored until the peptide was used up completely or when there was 
no change in peptide peak over a period of time. 
As peptides are less cationic when compared to platinum complexes, the first 
peak in each of cation exchange chromatogram corresponds to peptide (FMRF/ACTH) 
and the peaks that are eluted later on are platinum complexed to the peptide. However in 
case of reverse phase HPLC, in addition to peptide and platinum complex peaks; buffer 
solution peaks are also present. To overcome this, a blank containing only FMRF peptide 
was carried out.  The presence of Phenylalanine helps in the detection of this peptide at 
254 nm.  The retention time of FMRF peptide was averaged to ~ 3.25 minutes (Fig. 3.2.). 
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Figure 3.2. Chromatogram for FMRF peptide (RPLC, column 5cm x 4.6mm, mobile 
phase pH = 2, wavelength = 254 nm) 
A. Reactions of chlorodiethylenetriammineplatinum [II] chloride ([Pt(dien)Cl]Cl) 
with peptides 
([Pt(dien)Cl]Cl (Fig. 3.3.) differs from other platinum complexes used in this 
study by containing a triamine group, one coordinating position and a chloride leaving 
group. It has molecular weight of 369.16 g. Chloride is a strong leaving group when 
compared to nitrate of other platinum complexes used in this study.  
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Figure 3.3. Structure of ([Pt(dien)Cl]Cl 
   
[Pt(dien)Cl]Cl was reacted with FMRF and ACTH peptide and the reaction was 
monitored by cation exchange chromatography. 0.8 mg of [Pt(dien)Cl]Cl was weighed 
and dissolved in 1 ml of deionized water in a glass vial and 1.2 mg of FMRF was added. 
In another vial 1mg of [Pt(dien)Cl]Cl was dissolved  in 1 ml of deionized water and 4 mg 
of ACTH was added. In both cases, equal molar ratios were used and the analysis of each 
peptide was done with a gap of few days. 
In case of [Pt(dien)Cl]Cl/FMRF system, the retention time of FMRF was 5.0-12.5 
mins and the adducts had broad peaks with a retention time of 17- 42.5 mins. FMRF 
reacted completely with [Pt(dien)Cl]Cl in 50 hrs (Fig. 3.4.).  
In case of [Pt(dien)Cl]Cl/ACTH system, the retention time of ACTH was 5.0-12.5 
mins and the presence of adduct formation was seen as a broad peak that started to appear 
within 25-42.5 mins. The reaction was completed within 21 hours (Fig. 3.5.). 
The reaction of [Pt(dien)Cl]Cl with FMRF and ACTH peptide was very slow. 
This could be due to presence of a chloride leaving group. The presence of one 
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coordinating position may also effect the reaction but to a lesser extent than the weak 
leaving group.  
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Figure 3.4. Cation exchange chromatography chromatograms for the 
[Pt(dien)Cl]Cl/FMRF system at a molar ratio of 1:1 (column 5cm x 4.6mm, mobile phase 
pH = 6, wavelength = 254 nm) (a) T ~ 0h (b) T ~ 7 h (c) T ~ 13 h (d) T ~ 50 h 
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Figure 3.5. Cation exchange chromatography chromatograms for the 
[Pt(dien)Cl]Cl/ACTH system at a molar ratio of 1:1 (column 5cm x 4.6mm, mobile 
hase pH = 6, wavelength = 280 nm) (a) T ~ 0h (b) T ~ 5 h (c) T ~ 10 h (d) T ~ 21 h 
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B.         Reactions of ethylenediamminedinitroplatinum [II] (Pt(en)(NO3)2) with peptides 
 Pt(en)(NO3)2 (Fig. 3.6.) is similar to cisplatin except for the presence of ethylene 
bridge and nitrates as leaving groups. It has two coordinating positions owing to the 
presence of two nitrate leaving groups. It has a molecular weight of 405.2 g. The reaction 
of Pt(en)(NO3)2 with ACTH and FMRF peptide was monitored by cation exchange and 
reverse phase HPLC methods. 
 
 
 
Figure 3.6. Structure of Pt(en)(NO3)2 
B.1. Cation Exchange Chromatrography of Pt(en)(NO3)2/FMRF and Pt(en)(NO3)2/ACTH 
For cation exchange chromatography, two portions of 0.8 mg of Pt(en)(NO3)2 
were weighed and dissolved separately in 1 ml D.I water in two glass vials. 1.2 mg of 
FMRF was weighed and added to one vial and 2.5 mg of ACTH was weighed and added 
to the other vial. Each reaction was monitored at fixed intervals until all the peptide was 
reacted completely.  
For Pt(en)(NO3)2/FMRF system, the retention time of FMRF was 5.0-7.5 mins 
and the adducts appeared as broad peak that had retention time of  20.0-42.5 mins. The 
reaction was completed in 10 hours (Fig. 3.7.). 
NH2 NH2
NO3 NO3
Pt
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For Pt(en)(NO3)2/ACTH system, the retention time of ACTH was 5.0-8.0 mins. 
Five adducts could be formed nevertheless not well separated. The reaction was 
completed in 7 hours (Fig. 3.8.). 
Pt(en)(NO3)2 reacted with both peptides quite fast compared to [Pt(dien)Cl]Cl. 
This is mainly due to the presence of nitrate leaving groups. Nitrates are better leaving 
groups than chlorides. When Pt(en)(NO3)2 was reacted with ACTH, formation of more 
than one product is seen. It is quite possible that in addition to methionine residues 
Pt(en)(NO3)2 chelated with histidine functional groups in different coordination modes. 
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Figure 3.7. Cation exchange chromatography chromatograms for the 
[Pt(en)NO3)2]/FMRF system at a molar ratio of 1:1 (column 5cm x 4.6mm, mobile phase 
pH = 6, wavelength = 254 nm) (a) T ~ 0h (b) T ~ 3 h (c) T ~ 9 h (d) T ~ 10 h 
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Figure 3.8. Cation exchange chromatography chromatograms for the Pt(en)NO3)2 /ACTH 
system at a molar ratio of 1:1 (column 5cm x 4.6mm, mobile phase pH = 6, wavelength = 
280 nm) (a) T ~ 0h (b) T ~ 2 h (c) T ~ 5 h (d) T ~ 7 h 
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B.2. Reverse Phase Liquid Chromatography (RPLC) of Pt(en)(NO3)2/ FMRF 
The reaction of Pt (en) (NO3)2 and FMRF peptide was also monitored by RPLC 
method. In this method 1:1, 2:1 and 1:2 ratio of Pt(en)(NO3)2:FMRF was monitored.    
For 1:1 ratio 1.2 mg of FMRF and 0.8 mg of Pt (en)(NO3)2 was used.                                         
For 1:2 ratio 1.2 mg of FMRF and 1.6 mg of Pt (en)(NO3)2 was used.                                         
For 2:1 ratio 2.4 mg of FMRF and 0.8 mg of Pt (en)(NO3)2 was used. 
Sample for injection for these reactions were carried out in 1 ml of D.I. water.  
When 1:1 molar ratio of FMRF:Pt(en)(NO3)2 was monitored with RPLC, adducts 
formed very fast. This prompted us to check if there is a change in the rate of reaction or 
types of adducts when different molar ratios are used. As Pt(en)(NO3)2 reacted with 
FMRF very fast, the reaction was monitored at the intervals of 5 mins. In 1:1 ratio the 
reaction was over within a couple of minutes because of which only one adduct peak 
could be seen in the chromatogram (Fig. 3.9.) In 2:1(Fig.3.10.) and 1:2 (Fig.3.11.) molar 
ratios of Pt(en)(NO3)2:FMRF, conversion from minor adduct (retention time = 2.0-2.3 
mins) to major adduct (retention time = 2.4-2.9) over a period of time is observed. 
Moreover, in 1:2 Pt(en)(NO3)2:FMRF molar ratio, it is also observed that some amount of 
major adduct is converted back to minor adduct within 60 mins; which is confirmed by 
the decrease in the area of major adduct peak and appearance of minor adduct peak.  
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Figure 3.9. Reverse phase liquid chromatography chromatograms for the 
[Pt(en)(NO3)2]/FMRF system at a molar ratio of 1:1 (column 2.1 x 150 mm, mobile phase 
pH = 2, wavelength = 254 nm) (a) T ~ 0 (b)  ~ 6 mins (c) T ~ 12 mins (d) T ~18 mins 
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Figure 3.10. Reverse phase liquid chromatography chromatograms for the [Pt(en)(NO3)2] 
/FMRF system at a molar ratio of 2:1 (column 2.1 x 150 mm, mobile phase pH = 2, 
wavelength = 254 nm) (a) T ~ 0 (b) T ~ 6 mins (c) T ~ 12 mins (d) T ~ 22 mins 
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Figure 3.11. Reverse phase liquid chromatography chromatograms for the 
[Pt(en)(NO3)2]/FMRF system at a molar ratio of 1:2 (column 2.1 x 150 mm, mobile phase 
pH = 2, wavelength = 254 nm) (a) T ~ 0 (b) T ~ 25 mins (c) T ~ 30 mins (d) T ~ 60mins 
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C. Reactions of ethylenediamminetetramethyldinitroplatinum [II] (Pt(Me4en)(NO3)2) 
with peptides 
Pt(Me4en)(NO3)2 (Fig.3.12.) is the bulkiest platinum complex used in this study. 
The molecular weight of Pt(Me4en)(NO3)2 is 435.2g. It has two methyl groups on each 
amino group in addition to the ethylene bridge. Due to the presence of two nitrate groups, 
it can coordinate with two groups. The reaction of Pt(Me4en)(NO3)2 was analyzed by 
cation exchange HPLC and reverse phase HPLC. Due to increase in pump pressure the 
reaction of Pt(Me4en)(NO3)2 with ACTH could not be analyzed by HPLC. 
                                         
 
 
 
Figure 3.12 Structure of Pt(Me4en)(NO3)2 
C.1. Cation exchange chromatography of Pt(Me4en)(NO3)2/FMRF 
For Cation exchange chromatography, 0.8 mg of Pt(Me4en)(NO3)2 was dissolved 
in    1 ml of D.I. water and reacted with 1.2 mg of FMRF to get 1:1 molar ratio. The 
reaction was monitored at fixed intervals until all the peptide was reacted completely. 
The retention time of unreacted FMRF peptide was 5-15 mins and adduct appeared as a 
broad peak after ~ 20 mins (Fig.3.13.). The reaction was completed in 25 hours. 
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Figure 3.13. Cation exchange chromatography chromatograms for the 
[Pt(Me4en)(NO3)2]/FMRF system at a molar ratio of 1:1 (column 5cm x 4.6mm, mobile 
phase pH = 6, wavelength = 254 nm) (a) T ~ 0h(b) T ~ 2 h (c) T ~ 5 h (d) T ~ 25 h 
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C.2  Reverse Phase Liquid Chromatography (RPLC) of Pt(Me4en)(NO3)2 / FMRF 
The reaction of Pt(Me4en)(NO3)2 with FMRF was also monitored by RPLC 
method. In this 1.2 mg of FMRF and 0.8 mg of Pt(Me4en)(NO3)2 were mixed in 1 ml of 
D.I. water
 
to obtain 1:1 molar ratio. The reaction was monitored at fixed intervals until 
the peptide was reacted completely. 
 By comparing the chromatogram (Fig. 3.14.) with the blank runs of FMRF 
peptide, and buffer solution, it is assumed that the retention time of FMRF peptide is 4-5 
mins. Five adducts, 4 minor and 1 major adduct with retention time of ~ 6 mins, 7 mins, 
10 mins, 22-24 mins and 8-9 respectively are formed. The major adduct (retention time 8-
9 mins) is converted slowly to a minor adduct which is eluted after 22 mins. Formation of 
multiple adducts is due to different coordination modes by which platinum can interact 
with the methionine. 
Overall, the reaction Pt (Me4en)(NO3)2 with FMRF peptide was very slow as the 
reaction was completed in 25 hrs and 73 hrs for cation exchange and reverse phase HPLC 
methods respectively. The reason behind decreased rate of reaction could be due to 
increase in bulk on amine ligands by addition of 2 methyl groups on amine nitrogens. 
This increase in bulk may lead to steric interaction causing delay in the reaction. 
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Figure 3.14. Reverse phase liquid chromatography chromatograms for the 
[Pt(Me4en)(NO3)2]/FMRF system at a molar ratio of 1:1 (column 2.1 x 150 mm, mobile 
phase pH = 2, wavelength = 254 nm) (a) T ~ 0h(b) T ~ 1 h (c) T ~ 24 h (d) T ~ 48h (e) T 
~ 73 h 
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IV. DISCUSSION 
 The reactions of platinum complexes with peptides were possible to monitor by 
the use of HPLC. Reverse Phase Liquid Chromatography (RPLC) proved to be very 
efficient in terms of better separation and symmetric peaks. With the present RPLC 
method, analysis could not be carried out for reactions of ACTH peptide and 
FMRF/[Pt(dien)Cl]Cl system due to increased complexity of the reaction. 
This research was conducted to study the effects of leaving groups and bulk of 
amine ligands on the reaction of platinum complexes with sulfur containing peptides. In 
order to evaluate effects of increased bulk on amine ligands in a platinum complex, the 
reactions of less bulky Pt(en)(NO3)2  was compared with bulkier Pt(Me4en)(NO3)2. To 
understand how the change in leaving groups affect the reactions of platinum complex 
with sulfur containing peptides, platinum complexes with almost equal bulk but with 
different leaving groups were studied. As [Pt(dien)Cl]Cl has the same amount of bulk as 
Pt(en)(NO3)2, the results from the reactions of these two platinum complexes were used 
to understand the effects of leaving group.  
Two peptides, FMRF and ACTH with varying amount of amino acids were 
utilized. FMRF is a small peptide with 4 amino acids & ACTH contains 10 amino acids. 
Both of these peptides contain internal methionine, to which platinum complexes bind. In 
addition to methionine group, ACTH also has histidine, containing N donor group, which 
may also bind to platinum complexes. The presence of histidine in the same amino acid 
was employed to study the intra molecular competition between S & N residues. The 
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effect of leaving groups on the platination of peptides was confirmed again by this study. 
Pt(en)(NO3)2 reacted faster than [Pt(dien)Cl]Cl with both peptides. From cation exchange 
chromatography results, it was found that Pt(en)(NO3)2 took 10 hrs and 7 hours to react 
with FMRF and ACTH respectively, Whereas  [Pt(dien)Cl]Cl took 50 hrs and 21 hrs to 
react with FMRF and ACTH respectively. As nitrates are better leaving groups than 
chlorides, Pt(en)(NO3)2 reacted faster than [Pt(dien)Cl]Cl. 
Effects of bulk of amine ligand in platinum complexes on the reaction with 
peptides were also proven with this study. It was found from the reaction times for the 
reaction of Pt(Me4en)(NO3)2 and Pt(en)(NO3)2. From the cation exchange 
chromatography data it was found that Pt(Me4en)(NO3)2 reacts slowly as it took 25 hrs to 
react with FMRF completely whereas Pt(en)(NO3)2  took only 10 hrs to react with FMRF. 
It was also confirmed from reverse phase liquid chromatography (RPLC) data, which 
show that Pt(en)(NO3)2 took few minutes whereas Pt(Me4en)(NO3)2  took around 3 days 
to react with FMRF peptide completely. Therefore as the bulk of amine ligand is 
increased the reaction slows down, possibly due to increase of steric hindrance. 
Intramolecular competition studies between sulfur and nitrogen containing 
residues of ACTH peptides could not be confirmed from the present study. However, it is 
possible that Pt(en)(NO3)2 reacts with both S & N groups of ACTH as more than one 
adduct peak is eluted in the chromatogram [Fig. 3.8.]. It is not possible to confirm this 
unless the structure of each adduct peak is elucidated. In the future it is intended that 
Preparative HPLC will be carried out to collect individual peaks of the reaction and 
Nuclear magnetic resonance (NMR) spectroscopy will be used to elucidate the structure.
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